Shah, MD, professor of endocrinology and director of diabetes clinical research at Indiana University School of Medicine, Indianapolis ... SAB Bio, and Vertex, with financial compensation received ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Severe thunderstorm warning in Indianapolis, Lawrence as worst of storm moves south A severe thunderstorm warning is in effect until 7:45 p.m. for the south side of Indianapolis and Hancock County ...

INDIANAPOLIS — The sun is starting to creep through the winter gray, temperatures are rising and baseball is back at Victory Field, sending a signal that summer is finally on its way. The ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

To stream 13 WTHR on your phone, you need the 13 WTHR app. 13 WTHR+ features the latest breaking news and weather, plus daily talk shows, coverage of your favorite sports teams from Locked On, ...

There is currently no schedule data. The Schedule Release will be available on April.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

LDL cholesterol and triglycerides are well known for their link to elevated cardiovascular risk. So too are the treatments, like statins, that can be used to tamp down high levels of either lipid.

Beyond beefing up its radiopharma pipeline, BMS is also building up manufacturing capabilities. Hickey said the pharma’s facility in Indianapolis “is now fully operational” and can contribute to ...